Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.